T he number of disclosed preclinical partnerships (excluding straight licensing deals) for academic institutions in 2015 was similar to 2014's (236 versus 237 deals) but 150 fewer than in 2012, when deal making was at its peak. Since then, the availability of partnering money has decreased, and consortia have become less popular. Similar to last year, Texas's and California's expansive public university systems dominate this list (Table 1) , with the former replacing the latter at the top. The most active pharma or big biotech in deal making was GlaxoSmithKline with 9 public deals (Fig. 1) ; AstraZeneca, which recorded 18 deals in 2014, added another seven in 2015. 
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